{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T09:05:15Z","timestamp":1776589515678,"version":"3.51.2"},"reference-count":17,"publisher":"Jaypee Brothers Medical Publishing","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.59556\/japi.73.1044","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:26:35Z","timestamp":1760081195000},"page":"68-71","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Edaravone in Amyotrophic Lateral Sclerosis: It is Safe but Does Not Stop Progression"],"prefix":"10.59556","volume":"73","author":[{"given":"Salil","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunny","family":"Tomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Anadure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoj","family":"Somashekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2914","reference":[{"key":"key20251010072633_B1","doi-asserted-by":"crossref","first-page":"512.","DOI":"10.1001\/archneur.58.3.512","article-title":"How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot.","volume":"58:","author":"Rowland","year":"2001;","journal-title":"Arch Neurol"},{"key":"key20251010072633_B2","doi-asserted-by":"crossref","first-page":"1767.","DOI":"10.1172\/JCI71601","article-title":"Emerging mechanisms of molecular pathology in ALS.","volume":"125:","author":"Peters","year":"2015;","journal-title":"J Clin Invest"},{"key":"key20251010072633_B3","doi-asserted-by":"crossref","first-page":"1218.","DOI":"10.1212\/WNL.0b013e3181bc0141","article-title":"Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"73:","author":"Miller","year":"2009;","journal-title":"Neurology"},{"key":"key20251010072633_B4","unstructured":"US Food and Drug. Administration. FDA approves drug to treat ALS. Available from: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm557102.htm"},{"issue":"(1\u20132):","key":"key20251010072633_B5","doi-asserted-by":"crossref","first-page":"13\u2013","DOI":"10.1016\/S0022-510X(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).","volume":"169","author":"Cedarbaum","year":"1999;","journal-title":"J Neurol Sci"},{"issue":"(1):","key":"key20251010072633_B6","doi-asserted-by":"crossref","first-page":"38\u2013","DOI":"10.1212\/01.WNL.0000148648.38313.64","article-title":"The ALSFRSr predicts survival time in an ALS clinic population.","volume":"64","author":"Kaufmann","year":"2005;","journal-title":"Neurology"},{"issue":"(2):","key":"key20251010072633_B7","doi-asserted-by":"crossref","first-page":"265\u2013","DOI":"10.1212\/01.wnl.0000194316.91908.8a","article-title":"Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS.","volume":"66","author":"Kimura","year":"2006;","journal-title":"Neurology"},{"issue":"(7\u20138):","key":"key20251010072633_B8","doi-asserted-by":"crossref","first-page":"610\u2013","DOI":"10.3109\/21678421.2014.959024","article-title":"Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.","volume":"15","author":"Abe","year":"2014;","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"(7):","key":"key20251010072633_B9","first-page":"505\u2013","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.","volume":"16","author":"Writing Group; Edaravone (MCI-186) ALS 19 Study Group.","year":"2017;","journal-title":"Lancet Neurol"},{"issue":"(2):","key":"key20251010072633_B10","doi-asserted-by":"crossref","first-page":"218.","DOI":"10.1002\/mus.26740","article-title":"Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19).","volume":"61","author":"Shefner","year":"2020;","journal-title":"Muscle Nerve"},{"issue":"(11):","key":"key20251010072633_B11","doi-asserted-by":"crossref","first-page":"3258\u2013","DOI":"10.1007\/s00415-020-09993-z","article-title":"The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis.","volume":"267","author":"Lunetta","year":"2020;","journal-title":"J Neurol"},{"issue":"(1):","key":"key20251010072633_B12","first-page":"1\u2013","article-title":"Safety and efficacy of edaravone in well-defined Iranian patients with amyotrophic lateral sclerosis: a parallel-group single-blind trial.","volume":"20","author":"Eishi-Oskouei","year":"2021;","journal-title":"Curr J Neurol"},{"issue":"(2):","key":"key20251010072633_B13","doi-asserted-by":"crossref","first-page":"121\u2013","DOI":"10.1001\/jamaneurol.2021.4893","article-title":"Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis.","volume":"79","author":"Witzel","year":"2022;","journal-title":"JAMA Neurol"},{"issue":"(1):","key":"key20251010072633_B14","doi-asserted-by":"crossref","first-page":"260.","DOI":"10.1186\/s12883-022-02788-x","article-title":"Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.","volume":"22","author":"Park","year":"2022;","journal-title":"BMC Neurol"},{"issue":"(4):","key":"key20251010072633_B15","doi-asserted-by":"crossref","first-page":"692\u2013","DOI":"10.4103\/aian.aian_1083_21","article-title":"Assessment of therapeutic response of edaravone and riluzole combination therapy in amyotrophic lateral sclerosis patients.","volume":"25","author":"Samadhiya","year":"2022;","journal-title":"Ann Indian Acad Neurol"},{"issue":"(1):","key":"key20251010072633_B16","doi-asserted-by":"crossref","first-page":"1\u2013","DOI":"10.1007\/s40261-022-01229-4","article-title":"Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.","volume":"43","author":"Gao","year":"2023;","journal-title":"Clin Drug Investig"},{"issue":"(1\u20132):","key":"key20251010072633_B17","doi-asserted-by":"crossref","first-page":"178.","DOI":"10.3109\/17482960903093710","article-title":"Clinical significance in the change of decline in ALSFRS-R.","volume":"11","author":"Castrillo-Viguera","year":"2010;","journal-title":"Amyotroph Lateral Scler"}],"container-title":["Journal of The Association of Physicians of India"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T07:26:38Z","timestamp":1760081198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.japi.org\/article\/japi-73-7-68"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.59556\/japi.73.1044"],"URL":"https:\/\/doi.org\/10.59556\/japi.73.1044","relation":{},"ISSN":["0004-5772"],"issn-type":[{"value":"0004-5772","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}